Harrow, a growing leader in the North American ophthalmic pharmaceutical market, is dedicated to delivering innovative, accessible, and affordable eyecare solutions.

Dec 31, 2024 · NASHVILLE, Tenn.--(BUSINESS WIRE)--Mar. 27, 2025-- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it …

Harrow owns an FDA-Registered 503B Outsourcing Facility and a patient-specific 503A pharmacy.

Since our founding in December 2011, Harrow has been dedicated to making medications more accessible and affordable. From humble beginnings with no products or customers, we have …

Jan 7, 2025 · Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

Harrow, a growing leader in the North American ophthalmic pharmaceutical market, is dedicated to delivering innovative, accessible, and affordable eyecare solutions.

Jan 29, 2024 · NASHVILLE, Tenn.--(BUSINESS WIRE)--Jan. 29, 2024-- Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the appointments …

Address. 1A Burton Hills Blvd., Suite 200 Nashville, TN 37215. Phone (615) 733 4730 (615) 733 4737 (Investor Relations) Social

Harrow is a growing leader in the ophthalmic healthcare market. Our success-to-date is directly tied to our unique approach to serving patients and supporting eyecare professionals.

Dec 31, 2024 · The Investor Relations website contains information about Harrow, Inc.'s business for stockholders, potential investors, and financial analysts.